A diverse team of Boston-based doctors and scientists has developed an approach that lets the patient's own body serve as a bioreactor to nurture an powerful immune reaction to cancer. The process recently began a two-year clinical trial on 25 patients at the Dana-Farber Cancer Center after it resulted in a 90 percent survival rate in an earlier study on mice with otherwise fatal cancer.
Pill-Sized Implant Enters Clinical Trials as Vaccine Against Deadly Cancer
Singularity Hub - 5 Oct 2013 00:05
A diverse team of Boston-based doctors and scientists has developed an approach that lets the patient's own body serve as a bioreactor to nurture an powerful immune reaction to cancer. The process recently began a two-year clinical trial on 25 patients at the Dana-Farber Cancer Center after it resulted in a 90 percent survival rate in an earlier study on mice with otherwise fatal cancer.
Share this Article
Recommended